Orphazyme no longer expects EMA decision this year
Orphazyme will likely have to wait until sometime during the first quarter of 2022 to receive a decision from the European Medicines Agency on its key candidate arimoclomol as a treatment for Niemann-Pick disease type C, the company reports.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Biotech company Orphazyme, which is based in Copenhagen, Denmark, must arm itself with more patience.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme expects to lay off 100 employees this year
For subscribers
Orphazyme to discuss NPC rejection with FDA in mid-October
For subscribers
Orphazyme may face class action suit from US investors
For subscribers
